Jacobson Pharma Corporation Limited

As of March 31, 2026, Jacobson Pharma Corporation Limited carries a market capitalization of 2.46B, placing it among publicly traded companies globally. Its enterprise value stands at 3.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jacobson Pharma Corporation Limited's next confirmed earnings release is scheduled for November 20, 2026.

As of March 31, 2026, Jacobson Pharma Corporation Limited has 2.00B shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Jacobson Pharma Corporation Limited maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Jacobson Pharma Corporation Limited's stock has declined approximately 35.86% over the past 52 weeks. The 50-day moving average sits at 0.99, while the 200-day moving average is 1.13.

As of March 31, 2026, Jacobson Pharma Corporation Limited holds 369.86M in cash and equivalents against 910.90M in total debt, resulting in a net debt position of 487.64M. Total book value stands at 2.32B, with working capital of 268.68M providing operational flexibility.